Aurobindo Pharma's China Facility Running at Loss, Eyes Break-Even by Q4
The company’s CFO, S. Subramanian, indicated that while the plant is operating below margin, it is ramping up production and is on track to contribute positively to the company’s EBITDA in the near future.
Aurobindo Pharma China | 24/11/2025 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy